DBP (DBP B) | Spotlight

Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The main focus is on the treatment of severe forms of cancer, infections and autoimmune diseases. The research is based on the company's proprietary technology. The products are sold under separate trademarks and collaboration on product development is done together with other players in the field. The company is based in Uppsala.

Quotes for Double Bond Pharmaceutical International AB

Right Now

+/-: -0.014
%: −4,79%
Latest: 0.278
High: 0.29
Low: 0.275
Volume: 66 310
Turnover (SEK): 18 463
Market Value (MSEK): 29,5
Time (Latest trade): 2025-04-03 16:16

Board

CEO

Igor Lokot

Chairperson of the Board

Sanna Rejnlander

Board

Igor Lokot
Irina Zaitseva
Sergey Yanitsky

Articles of association

News

2025-03-10 06:00:00 DBP International AB och Vivo Biopharma LLC förlänger avtalen om förvärv av tillgångar och samarbete
2025-03-10 06:00:00 DBP International AB and Vivo Biopharma LLC Extend Asset Purchase and Collaboration Agreements for SI-053
2025-02-27 05:00:00 DBP Bokslutskommuniké 2024
2025-02-19 11:38:46 DBP International AB optimerar tillverkningsprocessen för SI-053 inför fas 1-studie för glioblastom
2025-02-19 11:38:46 DBP International AB Optimizes Manufacturing Process for SI-053 Ahead of Phase 1 Clinical Trial in Glioblastoma

News agencies

2025-03-10 07:05:56 Finwire: Double Bond Pharma förlänger sina avtal med Vivo Biopharma
2025-03-10 06:25:08 Direkt: FÖRLÄNGER AVTAL MED VIVO OM KÖP OCH SAMARBETE FÖR SI-053
2025-02-27 06:25:42 Finwire: Double Bond Pharma minskar rörelseförlusten
2025-02-19 12:08:50 Finwire: Double Bond Pharma tar steg framåt för att påbörja klinisk fas
2025-01-13 14:36:07 Finwire: Double Bond Pharma ska driva verksamheten vidare

Analysis

2023-06-20 Mangold: Double Bond Pharma: Intressant läge - Mangold
2022-02-14 Mangold: Double Bond Pharma: Hjärntumör-projekt kan ta fart - Mangold
2021-05-05 Mangold: Double Bond Pharma: Sällsynt potential från öst - Mangold

Videos

Largest Owners

Name	Capital %	Votes %	Date
Igor Lokot	9,01	16,06	2024-12-23
KSDR Hamberg AB	7,82	7,21	2024-12-23
Per Ahlström	7,74	7,14	2024-12-23
Carl Carvalho	4,01	3,70	2024-12-23
QQM Fund Management AB	3,73	3,44	2025-02-28
Lars-Åke Börje Flarke	3,60	3,32	2024-12-23
Investentia AB	3,30	3,05	2024-12-23
Avanza Pension	2,73	2,52	2024-12-23
Magnus Hamberg	2,57	2,37	2024-12-23
Thomas Trumstedt	1,95	1,80	2024-12-23

** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Sanna Rejnlander	2022-07-13	en-US	Option i samband med incitamentsprogram	1 000 000	0,01	13 000,0	SEK
Irina Zaitseva	2022-07-13	en-US	Option i samband med incitamentsprogram	1 000 000	0,01	13 000,0	SEK
Igor Lokot	2022-07-13	en-US	Option i samband med incitamentsprogram	3 000 000	0,01	39 000,0	SEK
Igor Lokot	2021-05-12	Sell Transaction	DBP Ser B	- 27 969 000	0,01	−323 405,5	SEK
Yulia Mamaeva	2021-05-21	en-US	Double Bond Pharmaceutical BTU B	22 749	1,43	32 531,1	SEK
Igor Lokot	2021-01-20	Sell Transaction	Double Bond Pharmaceutical B	- 377 000	2,25	−848 250,0	SEK
Igor Lokot	2020-02-22	Sell Transaction	Double Bond Pharmaceutical International AB ser B TR	- 9 700 000	0	−0,0	SEK
Igor Lokot	2020-02-22	Sell Transaction	Double Bond Pharmaceutical International AB ser B Teckningsrätt	- 9 700 000	0	−0,0	SEK
Yulia Mamaeva	2020-02-28	en-US	Double Bond Pharmaceutical B	30 333	1,75	53 082,8	SEK
Igor Lokot	2020-02-28	en-US	Double Bond Pharmaceutical B	80 808	1,75	141 414,0	SEK
Yulia Mamaeva	2019-04-09	Sell Transaction	Double Bond Pharmaceutical UR	- 91 000	0	−91,0	SEK
Igor Lokot	2019-04-09	Sell Transaction	Double Bond Pharmaceutical UR	- 242 424	0	−242,4	SEK
Igor Lokot	2019-04-05	Sell Transaction	Double Bond Pharmaceutical UR	- 9 700 000	0,01	−48 500,0	SEK
Igor Lokot	2019-02-13	Sell Transaction	Double Bond Pharmaceutical B	- 100 000	8	−800 000,0	SEK
Igor Lokot	2018-11-16	Sell Transaction	Double Bond Pharmaceutical B	- 400 000	11,33	−4 532 000,0	SEK
Igor Lokot	2018-04-19	en-US	DBP BTA B	242 424	1,65	399 999,6	SEK
Igor Lokot	2018-04-06	en-US	DBP BTA B	2 550 000	1,65	4 207 500,0	SEK
Yulia Mamaeva	2018-04-06	en-US	DBP B BTA	22 750	1,65	37 537,5	SEK
Igor Lokot	2016-10-21	en-US	Double Bond Pharmaceutical B	- 500 000	7,4	−3 700 000,0	SEK

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

Number of months that the report spans	2024	Q4 3 Months	Q3 3 Months	Q2 3 Months	Q1 3 Months	2023	Q4 3 Months
Total revenue MSEK	1.09	0.22	0.23	0.20	0.44	1.37	0.25
Earnings before interest and tax MSEK	-7.76	-1.92	-1.72	-2.06	-2.06	-13.44	-3.25
Profit before tax MSEK	-13.24	-4.95	-0.93	-4.87	-2.49	-17.34	-7.09
Net profit MSEK	-13.24	-4.95	-0.93	-4.87	-2.49	-17.34	-7.09
Earnings per share SEK	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00
Dividend per share SEK	0.00					0.00
Equity MSEK	-2.13	-2.13	2.83	3.76	6.51	5.36	5.36
Fixed assets MSEK	0.09	0.09	0.10	0.12	0.14	0.17	0.17
Intangible assets MSEK	0.10	0.10	0.13	0.15	0.18	0.20	0.20
Current assets MSEK	5.60	5.60	2.60	3.78	2.78	5.02	5.02
Total asset MSEK	6.22	6.22	6.72	7.12	8.97	11.60	11.60
Long term liabilities MSEK	0.00	0.00	0.59	0.00	0.00	0.00	0.00
Current liabilities MSEK	8.35	8.35	3.89	3.37	2.46	6.24	6.24
Number of shares SEK	107.12	107.12	107.12	107.12	102.03	95.35	95.35

*Compiled data from Millistream

Upcoming reports

2025-05-01 Årsstämma 2024
2025-05-23 Delårsrapport 2025-Q1